Mineralys has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing ...

Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants ...

Mineralys Therapeutics has reported outcomes from its pivotal randomised, placebo-controlled Phase III Launch-HTN trial assessing lorundrostat for controlling hypertension. This global ...

Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants ...

Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Mineralys Therapeutics, Inc. announced that it will release its financial results for the first quarter ending March 31, 2025, after the market closes on May 12, 2025. A conference call will take ...

Investing.com -- Mineralys Therapeutics , Inc. (NASDAQ:MLYS) saw its stock jump 2.8% after reporting first quarter 2025 financial results that beat analyst expectations. The clinical-stage ...

Mineralys Therapeutics MLYS is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement. Analysts estimate that Mineralys ...

May 12, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney ...

Mineralys expects to announce top-line data from the Explore-CKD trial later in the current quarter. The Chief Executive Officer confirmed the company's intention to submit an NDA for lorundrostat ...

Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation ...

Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.